Drug intelligence / Profile preview

PRT939

Development stage: Unknown
Lead developer: Prothena
Modality: Small Molecules
Administration: Oral

Overview

PRT939 is a selective inhibitor of histone deacetylase 6 (HDAC6), a member of the histone deacetylase family of enzymes involved in epigenetic regulation. Developed by Prothena Biosciences, it is an oral small molecule designed to modulate HDAC6 activity, which plays a role in protein trafficking, immune cell function, and tumor microenvironment regulation, potentially offering therapeutic benefits in oncology and other indications through hyperacetylation of tubulin and disruption of aggresome pathways.

Targets

HDAC6 (Histone deacetylase 6)

Beyond the preview

Go deeper on PRT939.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRT939.

Explore the full profile